| Year |
Citation |
Score |
| 2023 |
Chantaravisoot N, Wongkongkathep P, Kalpongnukul N, Pacharakullanon N, Kaewsapsak P, Ariyachet C, Loo JA, Tamanoi F, Pisitkun T. mTORC2 interactome and localization determine aggressiveness of high-grade glioma cells through association with gelsolin. Scientific Reports. 13: 7037. PMID 37120454 DOI: 10.1038/s41598-023-33872-y |
0.806 |
|
| 2020 |
Nasimian A, Farzaneh P, Tamanoi F, Zahra Bathaie S. Cytosolic and mitochondrial ROS production resulted in apoptosis induction in breast cancer cells treated with Crocin: The role of FOXO3a, PTEN and AKT signaling. Biochemical Pharmacology. 113999. PMID 32353423 DOI: 10.1016/J.Bcp.2020.113999 |
0.351 |
|
| 2020 |
Tamanoi F, Mai NXD, Birault A, Matsumoto K, Ta HKT, Intasa-Ard SG, Morrison K, Thang PB, Doan TLH. Biodegradable Periodic Mesoporous Organosilica (BPMO) loaded with Daunorubicin: A Promising Nanoparticle-based Anti-cancer Drug. Chemmedchem. PMID 32020745 DOI: 10.1002/Cmdc.201900595 |
0.305 |
|
| 2019 |
Chantaravisoot N, Wongkongkathep P, Pacharakullanon N, Tamanoi F, Loo JA, Pisitkun T. Abstract 4535: The mTOR complex 2 promotes glioblastoma migration via the interactions with multiple actin-binding and microtubule-associated proteins Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-4535 |
0.732 |
|
| 2018 |
Matsumoto K, Le Hoang Doan T, Mai NXD, Nakai K, Komatsu A, Tamanoi F. Anticancer Drug Delivery Capability of Biodegradable PMO in the Chicken Egg Tumor Model. The Enzymes. 44: 103-116. PMID 30360810 DOI: 10.1016/Bs.Enz.2018.09.003 |
0.301 |
|
| 2018 |
Vu BT, Shahin SA, Croissant J, Fatieiev Y, Matsumoto K, Le-Hoang Doan T, Yik T, Simargi S, Conteras A, Ratliff L, Jimenez CM, Raehm L, Khashab N, Durand JO, Glackin C, ... Tamanoi F, et al. Chick chorioallantoic membrane assay as an in vivo model to study the effect of nanoparticle-based anticancer drugs in ovarian cancer. Scientific Reports. 8: 8524. PMID 29867159 DOI: 10.1038/S41598-018-25573-8 |
0.32 |
|
| 2018 |
Shahin SA, Wang R, Simargi SI, Contreras A, Parra L, Qu L, Wen W, Dellinger T, Unternaehrer J, Tamanoi F, Zink JI, Glackin CA. Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer. Nanomedicine : Nanotechnology, Biology, and Medicine. PMID 29665439 DOI: 10.1016/J.Nano.2018.04.008 |
0.389 |
|
| 2018 |
Faridi N, Bathaie SZ, Abroun S, Farzaneh P, Karbasian H, Tamanoi F, Mohagheghi MA. Isolation and characterization of the primary epithelial breast cancer cells and the adjacent normal epithelial cells from Iranian women's breast cancer tumors. Cytotechnology. PMID 29380298 DOI: 10.1007/S10616-017-0159-3 |
0.363 |
|
| 2018 |
Heard JJ, Phung I, Potes MI, Tamanoi F. An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation. Bmc Cancer. 18: 69. PMID 29320991 DOI: 10.1186/S12885-017-3938-5 |
0.422 |
|
| 2018 |
Chantaravisoot N, Wongkongkathep P, Pacharakullanon N, Tamanoi F, Loo JA, Pisitkun T. Abstract 2702: The mTOR complex 2-associated interactome and cell migration ability determination in brain cancers Cancer Research. 78: 2702-2702. DOI: 10.1158/1538-7445.Am2018-2702 |
0.782 |
|
| 2018 |
Contreras A, Shahin SA, Ratliff LE, Simargi SI, Wang R, Vu B, Dellinger TH, Zink JI, Tamanoi F, Unternaehrer-Hamm J, Glackin CA. Abstract 2152: Optimizing therapies for drug-resistant ovarian cancer stem cells using aCAM-PDX model Cancer Research. 78: 2152-2152. DOI: 10.1158/1538-7445.Am2018-2152 |
0.362 |
|
| 2017 |
Tanaka A, Radwan MO, Hamasaki A, Ejima A, Obata E, Koga R, Tateishi H, Okamoto Y, Fujita M, Nakao M, Umezawa K, Tamanoi F, Otsuka M. A novel inhibitor of farnesyltransferase with a zinc site recognition moiety and a farnesyl group. Bioorganic & Medicinal Chemistry Letters. PMID 28666734 DOI: 10.1016/J.Bmcl.2017.06.047 |
0.314 |
|
| 2017 |
Belaid A, Filippakis H, Lam H, Valvezan A, Huang R, Xia M, Wen T, Baglini C, Sakamuru S, Asara J, Sinh NT, Heard JJ, Tamanoi F, Austin C, Manning B, et al. Abstract A09: Therapeutic targeting of TSC2-deficient cells with Methotrexate: Results of a drug repurposing screen Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Pmccavuln16-A09 |
0.413 |
|
| 2017 |
Chantaravisoot N, Wongkongkathep P, Tamanoi F, Pisitkun T. Abstract 219: Identification of the mechanistic target of rapamycin complex 2-associated interactome involved in brain cancer cell motility by affinity purification-mass spectrometry Cancer Research. 77: 219-219. DOI: 10.1158/1538-7445.Am2017-219 |
0.731 |
|
| 2016 |
Roberts CM, Shahin SA, Wen W, Finlay JB, Dong J, Wang R, Dellinger TH, Zink JI, Tamanoi F, Glackin CA. Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models. Nanomedicine : Nanotechnology, Biology, and Medicine. PMID 27890656 DOI: 10.1016/J.Nano.2016.11.010 |
0.356 |
|
| 2016 |
Croissant J, Fatieiev Y, Julfakyan K, Lu J, Emwas A, Anjum D, Omar H, Tamanoi F, Zink J, Khashab N. Biodegradable Oxamide-Phenylene-Based Mesoporous Organosilica Nanoparticles with Unprecedented Drug Payloads for Delivery in Cells. Chemistry (Weinheim An Der Bergstrasse, Germany). PMID 27258139 DOI: 10.1002/Chem.201601714 |
0.343 |
|
| 2016 |
Croissant JG, Fatieiev Y, Omar H, Anjum DH, Gurinov A, Lu J, Tamanoi F, Zink JI, Khashab NM. Periodic Mesoporous Organosilica Nanoparticles with Controlled Morphologies and High Drug/Dye Loadings for Multicargo Delivery in Cancer Cells. Chemistry (Weinheim An Der Bergstrasse, Germany). PMID 27245497 DOI: 10.1002/Chem.201600587 |
0.305 |
|
| 2016 |
Croissant JG, Zhang D, Alsaiari S, Lu J, Deng L, Tamanoi F, Zink JI, Khashab NM. Protein-gold clusters-capped mesoporous silica nanoparticles for high drug loading, autonomous gemcitabine/doxorubicin co-delivery, and in-vivo tumor imaging. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 27016140 DOI: 10.1016/J.Jconrel.2016.03.030 |
0.31 |
|
| 2016 |
Zahra Bathaie S, Ashrafi M, Azizian M, Tamanoi F. Mevalonate Pathway and Human Cancers. Current Molecular Pharmacology. PMID 26758953 DOI: 10.2174/1874467209666160112123205 |
0.429 |
|
| 2015 |
Lu J, Yoshimura K, Goto K, Lee C, Hamura K, Kwon O, Tamanoi F. Nanoformulation of Geranylgeranyltransferase-I Inhibitors for Cancer Therapy: Liposomal Encapsulation and pH-Dependent Delivery to Cancer Cells. Plos One. 10: e0137595. PMID 26352258 DOI: 10.1371/Journal.Pone.0137595 |
0.395 |
|
| 2015 |
Bathaie SZ, Faridi N, Nasimian A, Heidarzadeh H, Tamanoi F. How Phytochemicals Prevent Chemical Carcinogens and/or Suppress Tumor Growth? The Enzymes. 37: 1-42. PMID 26298454 DOI: 10.1016/Bs.Enz.2015.06.003 |
0.345 |
|
| 2015 |
Chantaravisoot N, Wongkongkathep P, Loo JA, Mischel PS, Tamanoi F. Significance of filamin A in mTORC2 function in glioblastoma. Molecular Cancer. 14: 127. PMID 26134617 DOI: 10.1186/S12943-015-0396-Z |
0.756 |
|
| 2015 |
Finlay J, Roberts CM, Dong J, Zink JI, Tamanoi F, Glackin CA. Mesoporous silica nanoparticle delivery of chemically modified siRNA against TWIST1 leads to reduced tumor burden. Nanomedicine : Nanotechnology, Biology, and Medicine. PMID 26115637 DOI: 10.1016/J.Nano.2015.05.011 |
0.318 |
|
| 2015 |
Mortazavi F, Lu J, Phan R, Lewis M, Trinidad K, Aljilani A, Pezeshkpour G, Tamanoi F. Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis. Bmc Cancer. 15: 381. PMID 25956913 DOI: 10.1186/S12885-015-1360-4 |
0.327 |
|
| 2015 |
Sato T, Akasu H, Shimono W, Matsu C, Fujiwara Y, Shibagaki Y, Heard JJ, Tamanoi F, Hattori S. Rheb protein binds CAD (carbamoyl-phosphate synthetase 2, aspartate transcarbamoylase, and dihydroorotase) protein in a GTP- and effector domain-dependent manner and influences its cellular localization and carbamoyl-phosphate synthetase (CPSase) activity. The Journal of Biological Chemistry. 290: 1096-105. PMID 25422319 DOI: 10.1074/Jbc.M114.592402 |
0.418 |
|
| 2015 |
Hwang AA, Lu J, Tamanoi F, Zink JI. Functional nanovalves on protein-coated nanoparticles for in vitro and in vivo controlled drug delivery. Small (Weinheim An Der Bergstrasse, Germany). 11: 319-28. PMID 25196485 DOI: 10.1002/Smll.201400765 |
0.369 |
|
| 2015 |
Chantaravisoot N, Wongkongkathep P, Loo JA, Mischel PS, Tamanoi F. Significance of filamin A in mTORC2 function in glioblastoma Molecular Cancer. 14. DOI: 10.1186/s12943-015-0396-z |
0.675 |
|
| 2015 |
Finlay JB, Roberts CM, Lowe G, Peng L, Zink JI, Tamanoi F, Glackin CA. Abstract P2-07-04: Treatment of metastatic breast cancer using two nanoparticles combined with siRNA targeting Twist1 to inhibit EMT Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P2-07-04 |
0.373 |
|
| 2014 |
Bathaie SZ, Bolhassani A, Tamanoi F. Anticancer Effect and Molecular Targets of Saffron Carotenoids. The Enzymes. 36: 57-86. PMID 27102699 DOI: 10.1016/B978-0-12-802215-3.00004-5 |
0.315 |
|
| 2014 |
Nakashima A, Kamada S, Tamanoi F, Kikkawa U. Fission yeast arrestin-related trafficking adaptor, Arn1/Any1, is ubiquitinated by Pub1 E3 ligase and regulates endocytosis of Cat1 amino acid transporter. Biology Open. 3: 542-52. PMID 24876389 DOI: 10.1242/Bio.20148367 |
0.33 |
|
| 2014 |
Heard JJ, Fong V, Bathaie SZ, Tamanoi F. Recent progress in the study of the Rheb family GTPases Cellular Signalling. 26: 1950-1957. PMID 24863881 DOI: 10.1016/J.Cellsig.2014.05.011 |
0.373 |
|
| 2014 |
Croissant J, Chaix A, Mongin O, Wang M, Clément S, Raehm L, Durand JO, Hugues V, Blanchard-Desce M, Maynadier M, Gallud A, Gary-Bobo M, Garcia M, Lu J, Tamanoi F, et al. Two-photon-triggered drug delivery via fluorescent nanovalves. Small (Weinheim An Der Bergstrasse, Germany). 10: 1752-5. PMID 24678053 DOI: 10.1002/Smll.201400042 |
0.315 |
|
| 2014 |
Mortazavi F(, Lu J, Amir A, Phan R, Tamanoi F. Abstract A36: Interruption of K-Ras/PAK1/Crk pathway has a dramatic anti-tumor effect in NSCLC Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Rasonc14-A36 |
0.34 |
|
| 2014 |
lu J, Croissant J, Durand JJ, Guardado-Alvarez T, Zink JI, Tamanoi F. Abstract LB-9: Light-controllable nano-drug delivery system with deep tissue penetrating ability for cancer therapy with two-photon-triggered nanoimpellers Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-9 |
0.326 |
|
| 2013 |
Tamanoi F, Der CJ. Inhibitors of the Ras superfamily of small G-proteins. Preface. The Enzymes. 34: ix. PMID 25034107 DOI: 10.1016/B978-0-12-420146-0.09985-6 |
0.36 |
|
| 2013 |
Tamanoi F, Lu J. Recent progress in developing small molecule inhibitors designed to interfere with ras membrane association: toward inhibiting K-Ras and N-Ras functions. The Enzymes. 34: 181-200. PMID 25034105 DOI: 10.1016/B978-0-12-420146-0.00008-1 |
0.338 |
|
| 2013 |
Khazak V, Eyrisch S, Kato J, Tamanoi F, Golemis EA. A two-hybrid approach to identify inhibitors of the RAS-RAF interaction. The Enzymes. 33: 213-48. PMID 25033807 DOI: 10.1016/B978-0-12-416749-0.00010-5 |
0.363 |
|
| 2013 |
Tetlow AL, Tamanoi F. The Ras superfamily G-proteins. The Enzymes. 33: 1-14. PMID 25033798 DOI: 10.1016/B978-0-12-416749-0.00001-4 |
0.413 |
|
| 2013 |
Croissant J, Maynadier M, Gallud A, Peindy N'dongo H, Nyalosaso JL, Derrien G, Charnay C, Durand JO, Raehm L, Serein-Spirau F, Cheminet N, Jarrosson T, Mongin O, Blanchard-Desce M, Gary-Bobo M, ... ... Tamanoi F, et al. Two-photon-triggered drug delivery in cancer cells using nanoimpellers. Angewandte Chemie (International Ed. in English). 52: 13813-7. PMID 24214916 DOI: 10.1002/Anie.201308647 |
0.316 |
|
| 2013 |
Zimonjic DB, Chan LN, Tripathi V, Lu J, Kwon O, Popescu NC, Lowy DR, Tamanoi F. In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells. Bmc Cancer. 13: 198. PMID 23607551 DOI: 10.1186/1471-2407-13-198 |
0.66 |
|
| 2013 |
Akhavan D, Pourzia AL, Nourian AA, Williams KJ, Nathanson D, Babic I, Villa GR, Tanaka K, Nael A, Yang H, Dang J, Vinters HV, Yong WH, Flagg M, Tamanoi F, et al. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discovery. 3: 534-47. PMID 23533263 DOI: 10.1158/2159-8290.Cd-12-0502 |
0.329 |
|
| 2013 |
Yanes RE, Tarn D, Hwang AA, Ferris DP, Sherman SP, Thomas CR, Lu J, Pyle AD, Zink JI, Tamanoi F. Involvement of lysosomal exocytosis in the excretion of mesoporous silica nanoparticles and enhancement of the drug delivery effect by exocytosis inhibition. Small (Weinheim An Der Bergstrasse, Germany). 9: 697-704. PMID 23152124 DOI: 10.1002/Smll.201201811 |
0.769 |
|
| 2012 |
Nakashima A, Otsubo Y, Yamashita A, Sato T, Yamamoto M, Tamanoi F. Psk1, an AGC kinase family member in fission yeast, is directly phosphorylated and controlled by TORC1 and functions as S6 kinase Journal of Cell Science. 125: 5840-5849. PMID 22976295 DOI: 10.1242/Jcs.111146 |
0.36 |
|
| 2012 |
Rettig M, Trinidad K, Pezeshkpour G, Frost P, Sharma S, Moatamed F, Tamanoi F, Mortazavi F. PAK1 kinase promotes cell motility and invasiveness through CRK-II serine phosphorylation in non-small cell lung cancer cells. Plos One. 7: e42012. PMID 22848689 DOI: 10.1371/Journal.Pone.0042012 |
0.369 |
|
| 2012 |
Lau YA, Henderson BL, Lu J, Ferris DP, Tamanoi F, Zink JI. Continuous spectroscopic measurements of photo-stimulated release of molecules by nanomachines in a single living cell. Nanoscale. 4: 3482-9. PMID 22552632 DOI: 10.1039/C2Nr30524K |
0.339 |
|
| 2012 |
Yanes RE, Tamanoi F. Development of mesoporous silica nanomaterials as a vehicle for anticancer drug delivery. Therapeutic Delivery. 3: 389-404. PMID 22506096 DOI: 10.4155/Tde.12.9 |
0.769 |
|
| 2012 |
Lu J, Li Z, Zink JI, Tamanoi F. In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. Nanomedicine : Nanotechnology, Biology, and Medicine. 8: 212-20. PMID 21703996 DOI: 10.1016/J.Nano.2011.06.002 |
0.302 |
|
| 2012 |
Yanes RE, Lu J, Tamanoi F. Nanoparticle-Based Delivery of siRNA and miRNA for Cancer Therapy Enzymes. 32: 185-203. DOI: 10.1016/B978-0-12-404741-9.00009-X |
0.771 |
|
| 2011 |
Chan LN, Fiji HD, Watanabe M, Kwon O, Tamanoi F. Identification and characterization of mechanism of action of P61-E7, a novel phosphine catalysis-based inhibitor of geranylgeranyltransferase-I. Plos One. 6: e26135. PMID 22028818 DOI: 10.1371/Journal.Pone.0026135 |
0.635 |
|
| 2011 |
Tamanoi F. Ras signaling in yeast. Genes & Cancer. 2: 210-5. PMID 21779494 DOI: 10.1177/1947601911407322 |
0.349 |
|
| 2011 |
Ferris DP, Lu J, Gothard C, Yanes R, Thomas CR, Olsen JC, Stoddart JF, Tamanoi F, Zink JI. Synthesis of biomolecule-modified mesoporous silica nanoparticles for targeted hydrophobic drug delivery to cancer cells. Small (Weinheim An Der Bergstrasse, Germany). 7: 1816-26. PMID 21595023 DOI: 10.1002/Smll.201002300 |
0.79 |
|
| 2011 |
Hardt M, Chantaravisoot N, Tamanoi F. Activating mutations of TOR (target of rapamycin). Genes to Cells : Devoted to Molecular & Cellular Mechanisms. 16: 141-51. PMID 21210909 DOI: 10.1111/J.1365-2443.2010.01482.X |
0.765 |
|
| 2011 |
Chan LN, Watanabe M, Kwon O, Tamanoi F. Small-Molecule Inhibitors of GGTase-I from the Heterocycle Library Derived from Phosphine Catalysis Enzymes. 30: 165-177. DOI: 10.1016/B978-0-12-415922-8.00007-0 |
0.542 |
|
| 2011 |
Chan LN, Tamanoi F. Global Analysis of Prenylated Proteins by the Use of a Tagging via Substrate Approach Enzymes. 29: 195-206. DOI: 10.1016/B978-0-12-381339-8.00011-1 |
0.637 |
|
| 2010 |
Nakashima A, Tamanoi F. Conservation of the Tsc/Rheb/TORC1/S6K/S6 Signaling in Fission Yeast. The Enzymes. 28: 167-187. PMID 25814783 DOI: 10.1016/S1874-6047(10)28008-3 |
0.401 |
|
| 2010 |
Parmar N, Tamanoi F. Rheb G-Proteins and the Activation of mTORC1. The Enzymes. 27: 39-56. PMID 25429186 DOI: 10.1016/S1874-6047(10)27003-8 |
0.446 |
|
| 2010 |
Meng H, Xue M, Xia T, Zhao YL, Tamanoi F, Stoddart JF, Zink JI, Nel AE. Autonomous in vitro anticancer drug release from mesoporous silica nanoparticles by pH-sensitive nanovalves. Journal of the American Chemical Society. 132: 12690-7. PMID 20718462 DOI: 10.1021/Ja104501A |
0.318 |
|
| 2010 |
Hom C, Lu J, Liong M, Luo H, Li Z, Zink JI, Tamanoi F. Mesoporous silica nanoparticles facilitate delivery of siRNA to shutdown signaling pathways in mammalian cells. Small (Weinheim An Der Bergstrasse, Germany). 6: 1185-90. PMID 20461725 DOI: 10.1002/Smll.200901966 |
0.351 |
|
| 2010 |
Sato T, Nakashima A, Guo L, Coffman K, Tamanoi F. Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene. 29: 2746-52. PMID 20190810 DOI: 10.1038/Onc.2010.28 |
0.481 |
|
| 2010 |
Nakashima A, Sato T, Tamanoi F. Fission yeast TORC1 regulates phosphorylation of ribosomal S6 proteins in response to nutrients and its activity is inhibited by rapamycin. Journal of Cell Science. 123: 777-86. PMID 20144990 DOI: 10.1242/Jcs.060319 |
0.395 |
|
| 2010 |
Hanker AB, Mitin N, Wilder RS, Henske EP, Tamanoi F, Cox AD, Der CJ. Differential requirement of CAAX-mediated posttranslational processing for Rheb localization and signaling. Oncogene. 29: 380-91. PMID 19838215 DOI: 10.1038/Onc.2009.336 |
0.4 |
|
| 2010 |
Tamanoi F. Abstract LB-243: Discovery of single amino acid changes that confer constitutive activation of mTOR in human cancer Cancer Research. 70. DOI: 10.1158/1538-7445.Am10-Lb-243 |
0.462 |
|
| 2010 |
Chantaravisoot N, Tamanoi F. mTOR Signaling and Human Cancer The Enzymes. 28: 301-316. DOI: 10.1016/S1874-6047(10)28015-0 |
0.74 |
|
| 2009 |
Chan LN, Hart C, Guo L, Nyberg T, Davies BS, Fong LG, Young SG, Agnew BJ, Tamanoi F. A novel approach to tag and identify geranylgeranylated proteins. Electrophoresis. 30: 3598-606. PMID 19784953 DOI: 10.1002/Elps.200900259 |
0.621 |
|
| 2009 |
Lu J, Chan L, Fiji HD, Dahl R, Kwon O, Tamanoi F. In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I. Molecular Cancer Therapeutics. 8: 1218-26. PMID 19417142 DOI: 10.1158/1535-7163.Mct-08-1122 |
0.658 |
|
| 2009 |
Sato T, Nakashima A, Guo L, Tamanoi F. Specific activation of mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of its substrate protein. The Journal of Biological Chemistry. 284: 12783-91. PMID 19299511 DOI: 10.1074/Jbc.M809207200 |
0.405 |
|
| 2009 |
Zhou J, Vos CC, Gjyrezi A, Yoshida M, Khuri FR, Tamanoi F, Giannakakou P. The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner. The Journal of Biological Chemistry. 284: 9648-55. PMID 19228685 DOI: 10.1074/Jbc.M808708200 |
0.446 |
|
| 2008 |
Liong M, Lu J, Kovochich M, Xia T, Ruehm SG, Nel AE, Tamanoi F, Zink JI. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. Acs Nano. 2: 889-96. PMID 19206485 DOI: 10.1021/Nn800072T |
0.336 |
|
| 2008 |
Short JD, Houston KD, Dere R, Cai SL, Kim J, Johnson CL, Broaddus RR, Shen J, Miyamoto S, Tamanoi F, Kwiatkowski D, Mills GB, Walker CL. AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27. Cancer Research. 68: 6496-506. PMID 18701472 DOI: 10.1158/0008-5472.Can-07-5756 |
0.356 |
|
| 2008 |
Sato T, Umetsu A, Tamanoi F. Characterization of the Rheb-mTOR signaling pathway in mammalian cells: constitutive active mutants of Rheb and mTOR. Methods in Enzymology. 438: 307-20. PMID 18413257 DOI: 10.1016/S0076-6879(07)38021-X |
0.463 |
|
| 2008 |
Ikeda K, Morigasaki S, Tatebe H, Tamanoi F, Shiozaki K. Fission yeast TOR complex 2 activates the AGC-family Gad8 kinase essential for stress resistance and cell cycle control. Cell Cycle (Georgetown, Tex.). 7: 358-64. PMID 18235227 DOI: 10.4161/Cc.7.3.5245 |
0.396 |
|
| 2008 |
Watanabe M, Fiji HD, Guo L, Chan L, Kinderman SS, Slamon DJ, Kwon O, Tamanoi F. Inhibitors of protein geranylgeranyltransferase I and Rab geranylgeranyltransferase identified from a library of allenoate-derived compounds. The Journal of Biological Chemistry. 283: 9571-9. PMID 18230616 DOI: 10.1074/Jbc.M706229200 |
0.623 |
|
| 2008 |
Aspuria PJ, Tamanoi F. The Tsc/Rheb signaling pathway controls basic amino acid uptake via the Cat1 permease in fission yeast. Molecular Genetics and Genomics : Mgg. 279: 441-50. PMID 18219492 DOI: 10.1007/S00438-008-0320-Y |
0.354 |
|
| 2007 |
Lu J, Liong M, Sherman S, Xia T, Kovochich M, Nel AE, Zink JI, Tamanoi F. Mesoporous Silica Nanoparticles for Cancer Therapy: Energy-Dependent Cellular Uptake and Delivery of Paclitaxel to Cancer Cells. Nanobiotechnology : the Journal At the Intersection of Nanotechnology, Molecular Biology, and Biomedical Sciences. 3: 89-95. PMID 19936038 DOI: 10.1007/S12030-008-9003-3 |
0.378 |
|
| 2007 |
Aspuria PJ, Sato T, Tamanoi F. The TSC/Rheb/TOR signaling pathway in fission yeast and mammalian cells: temperature sensitive and constitutive active mutants of TOR. Cell Cycle (Georgetown, Tex.). 6: 1692-5. PMID 17637564 DOI: 10.4161/Cc.6.14.4478 |
0.433 |
|
| 2007 |
Castellano S, Fiji HD, Kinderman SS, Watanabe M, Leon Pd, Tamanoi F, Kwon O. Small-molecule inhibitors of protein geranylgeranyltransferase type I. Journal of the American Chemical Society. 129: 5843-5. PMID 17439124 DOI: 10.1021/Ja070274N |
0.368 |
|
| 2007 |
Yu F, Harada JN, Brown HJ, Deng H, Song MJ, Wu TT, Kato-Stankiewicz J, Nelson CG, Vieira J, Tamanoi F, Chanda SK, Sun R. Systematic identification of cellular signals reactivating Kaposi sarcoma-associated herpesvirus. Plos Pathogens. 3: e44. PMID 17397260 DOI: 10.1371/Journal.Ppat.0030044 |
0.351 |
|
| 2007 |
Urano J, Sato T, Matsuo T, Otsubo Y, Yamamoto M, Tamanoi F. Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells Proceedings of the National Academy of Sciences of the United States of America. 104: 3514-3519. PMID 17360675 DOI: 10.1073/Pnas.0608510104 |
0.46 |
|
| 2007 |
Matsuo T, Otsubo Y, Urano J, Tamanoi F, Yamamoto M. Loss of the TOR kinase Tor2 mimics nitrogen starvation and activates the sexual development pathway in fission yeast Molecular and Cellular Biology. 27: 3154-3164. PMID 17261596 DOI: 10.1128/Mcb.01039-06 |
0.374 |
|
| 2006 |
Patel PH, Tamanoi F. Increased Rheb-TOR signaling enhances sensitivity of the whole organism to oxidative stress. Journal of Cell Science. 119: 4285-92. PMID 17038544 DOI: 10.1242/Jcs.03199 |
0.606 |
|
| 2006 |
Gelb MH, Brunsveld L, Hrycyna CA, Michaelis S, Tamanoi F, Van Voorhis WC, Waldmann H. Therapeutic intervention based on protein prenylation and associated modifications. Nature Chemical Biology. 2: 518-28. PMID 16983387 DOI: 10.1038/Nchembio818 |
0.379 |
|
| 2006 |
Patel PH, Tamanoi F. Using Drosophila and yeast genetics to investigate a role for the Rheb GTPase in cell growth. Methods in Enzymology. 407: 443-54. PMID 16757344 DOI: 10.1016/S0076-6879(05)07036-9 |
0.68 |
|
| 2005 |
Urano J, Comiso MJ, Guo L, Aspuria PJ, Deniskin R, Tabancay AP, Kato-Stankiewicz J, Tamanoi F. Identification of novel single amino acid changes that result in hyperactivation of the unique GTPase, Rheb, in fission yeast. Molecular Microbiology. 58: 1074-86. PMID 16262791 DOI: 10.1111/J.1365-2958.2005.04877.X |
0.729 |
|
| 2005 |
Gau CL, Kato-Stankiewicz J, Jiang C, Miyamoto S, Guo L, Tamanoi F. Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways. Molecular Cancer Therapeutics. 4: 918-26. PMID 15956249 DOI: 10.1158/1535-7163.Mct-04-0347 |
0.543 |
|
| 2004 |
Kho Y, Kim SC, Jiang C, Barma D, Kwon SW, Cheng J, Jaunbergs J, Weinbaum C, Tamanoi F, Falck J, Zhao Y. A tagging-via-substrate technology for detection and proteomics of farnesylated proteins. Proceedings of the National Academy of Sciences of the United States of America. 101: 12479-84. PMID 15308774 DOI: 10.1073/Pnas.0403413101 |
0.522 |
|
| 2004 |
Aspuria PJ, Tamanoi F. The Rheb family of GTP-binding proteins. Cellular Signalling. 16: 1105-12. PMID 15240005 DOI: 10.1016/J.Cellsig.2004.03.019 |
0.487 |
|
| 2004 |
Uhlmann EJ, Li W, Scheidenhelm DK, Gau CL, Tamanoi F, Gutmann DH. Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation. Glia. 47: 180-8. PMID 15185396 DOI: 10.1002/Glia.20036 |
0.361 |
|
| 2004 |
Clarke S, Tamanoi F. Fighting cancer by disrupting C-terminal methylation of signaling proteins. The Journal of Clinical Investigation. 113: 513-5. PMID 14966560 DOI: 10.1172/Jci21059 |
0.389 |
|
| 2003 |
Patel PH, Thapar N, Guo L, Martinez M, Maris J, Gau CL, Lengyel JA, Tamanoi F. Drosophila Rheb GTPase is required for cell cycle progression and cell growth. Journal of Cell Science. 116: 3601-10. PMID 12893813 DOI: 10.1242/Jcs.00661 |
0.764 |
|
| 2003 |
Tabancay AP, Gau CL, Machado IM, Uhlmann EJ, Gutmann DH, Guo L, Tamanoi F. Identification of dominant negative mutants of Rheb GTPase and their use to implicate the involvement of human Rheb in the activation of p70S6K. The Journal of Biological Chemistry. 278: 39921-30. PMID 12869548 DOI: 10.1074/Jbc.M306553200 |
0.81 |
|
| 2003 |
Hamasaki A, Naka H, Tamanoi F, Umezawa K, Otsuka M. A novel metal-chelating inhibitor of protein farnesyltransferase. Bioorganic & Medicinal Chemistry Letters. 13: 1523-6. PMID 12699746 DOI: 10.1016/S0960-894X(03)00183-5 |
0.352 |
|
| 2002 |
Kato-Stankiewicz J, Hakimi I, Zhi G, Zhang J, Serebriiskii I, Guo L, Edamatsu H, Koide H, Menon S, Eckl R, Sakamuri S, Lu Y, Chen QZ, Agarwal S, Baumbach WR, ... ... Tamanoi F, et al. Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 99: 14398-403. PMID 12391290 DOI: 10.1073/Pnas.222222699 |
0.398 |
|
| 2001 |
Tamanoi F, Kato-Stankiewicz J, Jiang C, Machado I, Thapar N. Farnesylated proteins and cell cycle progression. Journal of Cellular Biochemistry. Supplement. 64-70. PMID 11842430 DOI: 10.1002/Jcb.10067 |
0.598 |
|
| 2001 |
Tamanoi F, Gau CL, Jiang C, Edamatsu H, Kato-Stankiewicz J. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells. Cellular and Molecular Life Sciences : Cmls. 58: 1636-49. PMID 11706990 DOI: 10.1007/Pl00000802 |
0.604 |
|
| 2001 |
Yang W, Tabancay AP, Urano J, Tamanoi F. Failure to farnesylate Rheb protein contributes to the enrichment of G0/G1 phase cells in the Schizosaccharomyces pombe farnesyltransferase mutant. Molecular Microbiology. 41: 1339-47. PMID 11580838 DOI: 10.1046/J.1365-2958.2001.02599.X |
0.799 |
|
| 2001 |
Finlin BS, Gau CL, Murphy GA, Shao H, Kimel T, Seitz RS, Chiu YF, Botstein D, Brown PO, Der CJ, Tamanoi F, Andres DA, Perou CM. RERG is a novel ras-related, estrogen-regulated and growth-inhibitory gene in breast cancer. The Journal of Biological Chemistry. 276: 42259-67. PMID 11533059 DOI: 10.1074/Jbc.M105888200 |
0.378 |
|
| 2001 |
Urano J, Ellis C, Clark GJ, Tamanoi F. Characterization of Rheb functions using yeast and mammalian systems. Methods in Enzymology. 333: 217-31. PMID 11400338 DOI: 10.1016/S0076-6879(01)33058-6 |
0.403 |
|
| 2001 |
Guo W, Tamanoi F, Novick P. Spatial regulation of the exocyst complex by Rho1 GTPase. Nature Cell Biology. 3: 353-60. PMID 11283608 DOI: 10.1038/35070029 |
0.336 |
|
| 2001 |
Urano J, Yang W, Tamanoi F. 3 Mutational analyses of protein farnesyltransferase The Enzymes. 21: 47-80. DOI: 10.1016/S1874-6047(01)80016-0 |
0.561 |
|
| 2001 |
Jiang C, Kato-Stankiewicz J, Gau C, Tamanoi F. Effects of farnesyltransferase inhibitors on cell cycle progression of human cancer cells Gene Function & Disease. 2: 99-107. DOI: 10.1002/1438-826X(200110)2:2/3<99::Aid-Gnfd99>3.0.Co;2-V |
0.764 |
|
| 2000 |
Edamatsu H, Gau CL, Nemoto T, Guo L, Tamanoi F. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. Oncogene. 19: 3059-68. PMID 10871858 DOI: 10.1038/Sj.Onc.1203625 |
0.354 |
|
| 2000 |
Urano J, Tabancay AP, Yang W, Tamanoi F. The Saccharomyces cerevisiae Rheb G-protein is involved in regulating canavanine resistance and arginine uptake. The Journal of Biological Chemistry. 275: 11198-206. PMID 10753927 DOI: 10.1074/Jbc.275.15.11198 |
0.797 |
|
| 2000 |
Yang W, Urano J, Tamanoi F. Protein farnesylation is critical for maintaining normal cell morphology and canavanine resistance in Schizosaccharomyces pombe. The Journal of Biological Chemistry. 275: 429-38. PMID 10617635 DOI: 10.1074/Jbc.275.1.429 |
0.607 |
|
| 1999 |
Del Villar K, Urano J, Guo L, Tamanoi F. A mutant form of human protein farnesyltransferase exhibits increased resistance to farnesyltransferase inhibitors. The Journal of Biological Chemistry. 274: 27010-7. PMID 10480914 DOI: 10.1074/Jbc.274.38.27010 |
0.429 |
|
| 1999 |
Robinson NG, Guo L, Imai J, Toh-E A, Matsui Y, Tamanoi F. Rho3 of Saccharomyces cerevisiae, which regulates the actin cytoskeleton and exocytosis, is a GTPase which interacts with Myo2 and Exo70. Molecular and Cellular Biology. 19: 3580-7. PMID 10207081 DOI: 10.1128/Mcb.19.5.3580 |
0.436 |
|
| 1999 |
Suzuki N, Urano J, Tamanoi F. Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. Proceedings of the National Academy of Sciences of the United States of America. 95: 15356-61. PMID 9860973 DOI: 10.1073/Pnas.95.26.15356 |
0.327 |
|
| 1998 |
Arellano M, Coll PM, Yang W, Duran A, Tamanoi F, Perez P. Characterization of the geranylgeranyl transferase type I from Schizosaccharomyces pombe. Molecular Microbiology. 29: 1357-67. PMID 9781874 DOI: 10.1046/J.1365-2958.1998.01009.X |
0.55 |
|
| 1998 |
Suzuki N, Del Villar K, Tamanoi F. Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents. Proceedings of the National Academy of Sciences of the United States of America. 95: 10499-504. PMID 9724732 DOI: 10.1073/Pnas.95.18.10499 |
0.404 |
|
| 1998 |
Scoles DR, Huynh DP, Morcos PA, Coulsell ER, Robinson NG, Tamanoi F, Pulst SM. Neurofibromatosis 2 tumour suppressor schwannomin interacts with betaII-spectrin. Nature Genetics. 18: 354-9. PMID 9537418 DOI: 10.1038/Ng0498-354 |
0.387 |
|
| 1997 |
Yang W, Del Villar K, Urano J, Mitsuzawa H, Tamanoi F. Advances in the development of farnesyltransferase inhibitors: substrate recognition by protein farnesyltransferase. Journal of Cellular Biochemistry. Supplement. 27: 12-9. PMID 9591188 DOI: 10.1002/(Sici)1097-4644(1997)27+<12::Aid-Jcb5>3.0.Co;2-4 |
0.539 |
|
| 1997 |
Upadhyaya M, Osborn MJ, Maynard J, Kim MR, Tamanoi F, Cooper DN. Mutational and functional analysis of the neurofibromatosis type 1 (NF1) gene. Human Genetics. 99: 88-92. PMID 9003501 DOI: 10.1007/S004390050317 |
0.337 |
|
| 1997 |
Del Villar K, Mitsuzawa H, Yang W, Sattler I, Tamanoi F. Amino acid substitutions that convert the protein substrate specificity of farnesyltransferase to that of geranylgeranyltransferase type I. The Journal of Biological Chemistry. 272: 680-7. PMID 8995312 DOI: 10.1074/Jbc.272.1.680 |
0.536 |
|
| 1997 |
Del Villar K, Dorin D, Sattler I, Urano J, Poullet P, Robinson N, Mitsuzawa H, Tamanoi F. C-terminal motifs found in Ras-superfamily G-proteins: CAAX and C-seven motifs. Biochemical Society Transactions. 24: 709-13. PMID 8878831 DOI: 10.1042/Bst0240709 |
0.318 |
|
| 1996 |
Morcos P, Thapar N, Tusneem N, Stacey D, Tamanoi F. Identification of neurofibromin mutants that exhibit allele specificity or increased Ras affinity resulting in suppression of activated ras alleles. Molecular and Cellular Biology. 16: 2496-503. PMID 8628317 DOI: 10.1128/Mcb.16.5.2496 |
0.399 |
|
| 1996 |
Tamanoi F, Mitsuzawa H. Use of yeast for identification of farnesyltransferase inhibitors and for generation of mutant farnesyltransferases. Methods in Enzymology. 255: 82-91. PMID 8524140 DOI: 10.1016/S0076-6879(95)55011-9 |
0.315 |
|
| 1995 |
Poullet P, Tamanoi F. [49] Use of yeast two-hybrid system to evaluate ras interactions with neurofibromin-GTPase-activating protein Methods in Enzymology. 255: 488-497. PMID 8524136 DOI: 10.1016/S0076-6879(95)55051-8 |
0.347 |
|
| 1995 |
Mitsuzawa H, Esson K, Tamanoi F. Mutant farnesyltransferase beta subunit of Saccharomyces cerevisiae that can substitute for geranylgeranyltransferase type I beta subunit. Proceedings of the National Academy of Sciences of the United States of America. 92: 1704-8. PMID 7878044 DOI: 10.1073/Pnas.92.5.1704 |
0.351 |
|
| 1995 |
Gelb MH, Tamanoi F, Yokoyama K, Ghomashchi F, Esson K, Gould MN. The inhibition of protein prenyltransferases by oxygenated metabolites of limonene and perillyl alcohol. Cancer Letters. 91: 169-75. PMID 7767906 DOI: 10.1016/0304-3835(95)03747-K |
0.364 |
|
| 1995 |
Mitsuzawa H, Tamanoi F. In vivo assays for farnesyltransferase inhibitors with Saccharomyces cerevisiae. Methods in Enzymology. 250: 43-51. PMID 7651169 DOI: 10.1016/0076-6879(95)50061-8 |
0.412 |
|
| 1995 |
Baba H, Fuss B, Urano J, Poullet P, Watson JB, Tamanoi F, Macklin WB. GapIII, a new brain-enriched member of the GTPase-activating protein family. Journal of Neuroscience Research. 41: 846-58. PMID 7500386 DOI: 10.1002/Jnr.490410615 |
0.388 |
|
| 1994 |
Poullet P, Lin B, Esson K, Tamanoi F. Functional significance of lysine 1423 of neurofibromin and characterization of a second site suppressor which rescues mutations at this residue and suppresses RAS2Val-19-activated phenotypes. Molecular and Cellular Biology. 14: 815-21. PMID 8264648 DOI: 10.1128/Mcb.14.1.815 |
0.446 |
|
| 1994 |
Cohen L, Mohr R, Chen YY, Huang M, Kato R, Dorin D, Tamanoi F, Goga A, Afar D, Rosenberg N. Transcriptional activation of a ras-like gene (kir) by oncogenic tyrosine kinases. Proceedings of the National Academy of Sciences of the United States of America. 91: 12448-52. PMID 7809057 DOI: 10.1073/Pnas.91.26.12448 |
0.377 |
|
| 1993 |
Hara M, Akasaka K, Akinaga S, Okabe M, Nakano H, Gomez R, Wood D, Uh M, Tamanoi F. Identification of Ras farnesyltransferase inhibitors by microbial screening. Proceedings of the National Academy of Sciences of the United States of America. 90: 2281-5. PMID 8460134 DOI: 10.1073/Pnas.90.6.2281 |
0.336 |
|
| 1993 |
Gomez R, Goodman LE, Tripathy SK, O'Rourke E, Manne V, Tamanoi F. Purified yeast protein farnesyltransferase is structurally and functionally similar to its mammalian counterpart. The Biochemical Journal. 289: 25-31. PMID 8424764 DOI: 10.1042/Bj2890025 |
0.346 |
|
| 1993 |
Tamanoi F. Inhibitors of Ras farnesyltransferases. Trends in Biochemical Sciences. 18: 349-53. PMID 8236454 DOI: 10.1016/0968-0004(93)90072-U |
0.358 |
|
| 1992 |
McNeel DG, Tamanoi F. Terminal region recognition factor 1, a DNA-binding protein recognizing the inverted terminal repeats of the pGKl linear DNA plasmids. Proceedings of the National Academy of Sciences of the United States of America. 88: 11398-402. PMID 1763054 DOI: 10.1073/Pnas.88.24.11398 |
0.317 |
|
| 1992 |
Tanaka K, Wood DR, Lin BK, Khalil M, Tamanoi F, Cannon JF. A dominant activating mutation in the effector region of RAS abolishes IRA2 sensitivity. Molecular and Cellular Biology. 12: 631-7. PMID 1732735 DOI: 10.1128/Mcb.12.2.631 |
0.417 |
|
| 1991 |
Finegold AA, Johnson DI, Farnsworth CC, Gelb MH, Judd SR, Glomset JA, Tamanoi F. Protein geranylgeranyltransferase of Saccharomyces cerevisiae is specific for Cys-Xaa-Xaa-Leu motif proteins and requires the CDC43 gene product but not the DPR1 gene product Proceedings of the National Academy of Sciences of the United States of America. 88: 4448-4452. PMID 2034682 DOI: 10.1073/Pnas.88.10.4448 |
0.374 |
|
| 1991 |
Tanaka K, Lin BK, Wood DR, Tamanoi F. IRA2, an upstream negative regulator of RAS in yeast, is a RAS GTPase-activating protein Proceedings of the National Academy of Sciences of the United States of America. 88: 468-472. PMID 1988946 DOI: 10.1073/Pnas.88.2.468 |
0.434 |
|
| 1991 |
Golubić M, Tanaka K, Dobrowolski S, Wood D, Tsai M, Marshall M, Tamanoi F, Stacey D. The GTPase stimulatory activities of the neurofibromatosis type 1 and the yeast IRA2 proteins are inhibited by arachidonic acid. The Embo Journal. 10: 2897-2903. DOI: 10.1002/J.1460-2075.1991.Tb07839.X |
0.426 |
|
| 1990 |
Tanaka K, Nakafuku M, Tamanoi F, Kaziro Y, Matsumoto K, Toh-e A. IRA2, a second gene of Saccharomyces cerevisiae that encodes a protein with a domain homologous to mammalian ras GTPase-activating protein. Molecular and Cellular Biology. 10: 4303-13. PMID 2164637 DOI: 10.1128/Mcb.10.8.4303 |
0.413 |
|
| 1990 |
Goodman LE, Judd SR, Farnsworth CC, Powers S, Gelb MH, Glomset JA, Tamanoi F. Mutants of Saccharomyces cerevisiae defective in the farnesylation of Ras proteins. Proceedings of the National Academy of Sciences of the United States of America. 87: 9665-9. PMID 2124698 DOI: 10.1073/Pnas.87.24.9665 |
0.429 |
|
| 1990 |
Xu GF, Lin B, Tanaka K, Dunn D, Wood D, Gesteland R, White R, Weiss R, Tamanoi F. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell. 63: 835-41. PMID 2121369 DOI: 10.1016/0092-8674(90)90149-9 |
0.41 |
|
| 1990 |
Finegold AA, Schafer WR, Rine J, Whiteway M, Tamanoi F. Common modifications of trimeric G proteins and ras protein: involvement of polyisoprenylation. Science (New York, N.Y.). 249: 165-9. PMID 1695391 DOI: 10.1126/Science.1695391 |
0.444 |
|
| 1990 |
Judd SR, Tamanoi F. A genetic approach to the study of farnesylation Methods. 1: 246-252. DOI: 10.1016/S1046-2023(05)80324-X |
0.376 |
|
| 1989 |
Goodman LE, Perou CM, Fujiyama A, Tamanoi F. Structure and expression of yeast DPR1, a gene essential for the processing and intracellular localization of ras proteins. Yeast (Chichester, England). 4: 271-81. PMID 3064491 DOI: 10.1002/Yea.320040405 |
0.421 |
|
| 1989 |
Cobitz AR, Yim EH, Brown WR, Perou CM, Tamanoi F. Phosphorylation of RAS1 and RAS2 proteins in Saccharomyces cerevisiae. Proceedings of the National Academy of Sciences of the United States of America. 86: 858-62. PMID 2492665 DOI: 10.1073/Pnas.86.3.858 |
0.354 |
|
| 1988 |
Tamanoi F, Hsueh EC, Goodman LE, Cobitz AR, Detrick RJ, Brown WR, Fujiyama A. Posttranslational modification of ras proteins: detection of a modification prior to fatty acid acylation and cloning of a gene responsible for the modification. Journal of Cellular Biochemistry. 36: 261-73. PMID 3288644 DOI: 10.1002/Jcb.240360307 |
0.382 |
|
| 1987 |
Fujiyama A, Matsumoto K, Tamanoi F. A novel yeast mutant defective in the processing of ras proteins: assessment of the effect of the mutation on processing steps. The Embo Journal. 6: 223-228. DOI: 10.1002/J.1460-2075.1987.Tb04742.X |
0.451 |
|
| 1985 |
Broek D, Samiy N, Fasano O, Fujiyama A, Tamanoi F, Northup J, Wigler M. Differential activation of yeast adenylate cyclase by wild-type and mutant RAS proteins. Cell. 41: 763-9. PMID 3891097 DOI: 10.1016/S0092-8674(85)80057-X |
0.399 |
|
| 1984 |
Tamanoi F, Walsh M, Kataoka T, Wigler M. A product of yeast RAS2 gene is a guanine nucleotide binding protein. Proceedings of the National Academy of Sciences of the United States of America. 81: 6924-8. PMID 6438624 DOI: 10.1073/Pnas.81.22.6924 |
0.385 |
|
| 1984 |
Fasano O, Aldrich T, Tamanoi F, Taparowsky E, Furth M, Wigler M. Analysis of the transforming potential of the human H-ras gene by random mutagenesis. Proceedings of the National Academy of Sciences of the United States of America. 81: 4008-12. PMID 6330729 DOI: 10.1073/Pnas.81.13.4008 |
0.379 |
|
| 1984 |
Hughes S, Mellstrom K, Kosik E, Tamanoi F, Brugge J. Mutation of a termination codon affects src initiation. Molecular and Cellular Biology. 4: 1738-46. PMID 6092936 DOI: 10.1128/Mcb.4.9.1738 |
0.35 |
|
| 1982 |
Stillman BW, Tamanoi F, Mathews MB. Purification of an adenovirus-coded DNA polymerase that is required for initiation of DNA replication. Cell. 31: 613-23. PMID 6297776 DOI: 10.1016/0092-8674(82)90317-8 |
0.339 |
|
| Show low-probability matches. |